- Home
- SLGL vs PIII Comparison
SLGL vs PIII Comparison
Compare SLGL & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- PIII
- Stock Information
- Founded
- SLGL 1997
- PIII 2015
- Country
- SLGL Israel
- PIII United States
- Employees
- SLGL N/A
- PIII N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- SLGL Health Care
- PIII Health Care
- Exchange
- SLGL Nasdaq
- PIII Nasdaq
- Market Cap
- SLGL 19.3M
- PIII 20.8M
- IPO Year
- SLGL 2018
- PIII N/A
- Fundamental
- Price
- SLGL $11.00
- PIII $7.27
- Analyst Decision
- SLGL Buy
- PIII Buy
- Analyst Count
- SLGL 1
- PIII 2
- Target Price
- SLGL $40.00
- PIII $16.25
- AVG Volume (30 Days)
- SLGL 10.1K
- PIII 4.7K
- Earning Date
- SLGL 08-15-2025
- PIII 08-06-2025
- Dividend Yield
- SLGL N/A
- PIII N/A
- EPS Growth
- SLGL N/A
- PIII N/A
- EPS
- SLGL N/A
- PIII N/A
- Revenue
- SLGL $12,103,000.00
- PIII $1,485,192,000.00
- Revenue This Year
- SLGL N/A
- PIII N/A
- Revenue Next Year
- SLGL $31.17
- PIII $7.92
- P/E Ratio
- SLGL N/A
- PIII N/A
- Revenue Growth
- SLGL 603.66
- PIII 9.79
- 52 Week Low
- SLGL $3.34
- PIII $6.00
- 52 Week High
- SLGL $16.50
- PIII $32.54
- Technical
- Relative Strength Index (RSI)
- SLGL 80.53
- PIII 62.71
- Support Level
- SLGL $9.17
- PIII $6.30
- Resistance Level
- SLGL $8.49
- PIII $7.51
- Average True Range (ATR)
- SLGL 0.68
- PIII 0.36
- MACD
- SLGL 0.33
- PIII 0.15
- Stochastic Oscillator
- SLGL 97.35
- PIII 84.11
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.